Equity Overview
Price & Market Data
Price: $21.69
Daily Change: -$0.451 / 2.08%
Daily Range: $21.32 - $22.16
Market Cap: $2,372,208,640
Daily Volume: 1,080,524
Performance Metrics
1 Week: -4.19%
1 Month: -13.55%
3 Months: 20.38%
6 Months: 124.7%
1 Year: 112.7%
YTD: 0.09%
Company Details
Employees: 118
Sector: Health technology
Industry: Biotechnology
Country:
Details
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.